Grifols SA
OTC:GIFLF
Grifols SA
OTC:GIFLF
Price:
13.9
USD
-0.71%
Market Closed
Market Cap:
$9.4B
Relative Value
The Relative Value of one
GIFLF
stock under the Base Case scenario is
48.08
USD.
Compared to the current market price of 13.9 USD,
Grifols SA
is
Undervalued by 71%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GIFLF
Relative Value
Base Case
48.08
USD
Undervaluation 71%
Multiples Across Competitors
GIFLF Competitors Multiples
Grifols SA Competitors
Grifols SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| ES |
|
Grifols SA
OTC:GIFLF
|
7.5B USD | 1 | 20.4 | 7.5 | 11.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
394.1B USD | 6.6 | 167.9 | 16.3 | 23.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.3B USD | 5.5 | 26.4 | 15.1 | 15.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188.3B USD | 6.5 | 23.2 | 15.8 | 15.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.5B USD | 10.2 | 32.5 | 23.9 | 24.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.8B USD | 5.7 | 18.1 | 15.4 | 17.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
89B AUD | 4 | 20.6 | 13.8 | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR | 14.1 | 33 | 56.3 | 57.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
